Search

Displaying results 1301 - 1310 of 7604 in total
  1. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970]

    Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Chromic chloride

    go.drugbank.com/drugs/DB09129
    Approved

    Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: Addaven Concentrate for Solution for Infusion, ADDAVEN CONCENTRATE FOR SOLUTION FOR INFUSIONCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Fenoldopam

    go.drugbank.com/drugs/DB00800
    Approved

    A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

    Categories: Antihypertensive Agents Indicated for Hypertension
  4. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a with or without … First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Flosequinan

    go.drugbank.com/drugs/DB13228
    ApprovedWithdrawn

    Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]

  6. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    Approvals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893). … [L42975] In 1963, metamizole was withdrawn from the Canadian market and banned in the UK, France, Sweden, Norway and Australia.

    Products: DIPIRONA 1 GAMPOLLA POR 2 ML
  7. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers. … Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.

  8. Drug

    Reboxetine

    go.drugbank.com/drugs/DB00234
    ApprovedInvestigationalWithdrawn

    Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra.

  9. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … the use of baricitinib for the treatment of COVID-19 in May 2022.

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    Yellow Fever Vaccine is a subcutaneously administered vaccination for the active immunization and prophylaxis of yellow fever in pediatric patients 9 months of age and older. … The FDA recommends vaccination with Yellow Fever Vaccine for persons living in or travelling to endemic areas and for laboratory personnel who handle virulent yellow fever virus or concentrated preparations

    Categories: Antiinfectives for Systemic Use